Payer Coverage
Coherus Solutions™ Payer
Coherus Solutions™ Payer
Coverage TOOL
UDENYCA® (pegfilgrastim-cbqv)
Coverage Announcements
As payers make coverage policy changes and announcements regarding UDENYCA®, you can stay informed by checking the announcements below.
-
February 2021
Texas Medicaid has designated UDENYCA® the preferred pegfilgrastim on the Preferred Drug List (PDL).
Read more: Texas Health and Human Services: Medicaid Pharmacy Prior Authorization and Preferred Drug List -
February 2021
Aetna has designated UDENYCA® and the reference product as co-preferred pegfilgrastims under the Commercial Medical Benefit.
Read more: Hematopoietic Colony-Stimulating Factors (CSFs) - Medical Clinical Policy Bulletins | Aetna. -
February 2021
Anthem has designated UDENYCA® and the reference product as co-preferred pegfilgrastims covered under the Commercial and Medicare Medical Benefit.
Read more: Anthem Clinical Criteria: Colony Stimulating Factor Agents. -
January 2021
TRICARE® has designated UDENYCA® as a preferred pegfilgrastim and available without a prior authorization (PA).
Read more: TRICARE Formulary Search -
January 2021
UnitedHealthcare and Optum have designated UDENYCA® the co-preferred pegfilgrastim for Medicare Advantage.
Read more: UnitedHealthcare® Medicare Advantage Policy Guideline: Colony Stimulating Factors -
January 2021
Blue Shield of California has designated UDENYCA®, the reference product, and pegfilgrastim-bmez as preferred pegfilgrastims covered under the Commercial Medical Benefit.
-
September 2020
Independent Health Medicare Policies has updated UDENYCA® to be the Preferred Agent with the reference product
-
August 2020
Select Health has updated UDENYCA® to be the Preferred Agent with pegfilgrastim-jmdb
Read more: Select Health has updated UDENYCA® (pegfilgrastim-cbqv) to be the Preferred Agent with Fulphila® (pegfilgrastim-jmdb) -
June 2020
Florida Medicaid has updated UDENYCA® to be the Preferred Agent
Read more: Florida Medicaid has updated UDENYCA® (pegfilgrastim-cbqv) to be the Preferred Agent -
May 2020
Minnesota Medicaid has updated UDENYCA® to be the Preferred Agent with all other pegfilgrastim biosimilars
Read more: Minnesota Medicaid has updated UDENYCA® (pegfilgrastim-cbqv) to be the Preferred Agent with all other pegfilgrastim biosimilars -
March 2020
Short Term Recommendations from NCCN Guidelines® & ASCO® Regarding use of Hematopoietic Growth Factors during COVID-19 Pandemic*
Read More: NCCN Guidelines for Hematopoietic Growth Factors: Short-Term Recommendations Specific to Issues with COVID-19 (SARS-CoV-2)
Due to COVID-19 pandemic, the short-term recommendations from the NCCN Guidelines® and ASCO® have lowered the threshold for the use of myeloid growth factors from those chemotherapy regimens which have a 20% or higher risk of febrile neutropenia to now include those regimens with a risk of 10-20%, which includes all of the intermediate risk chemotherapy regimens.
Read More: ASCO COVID-19 Update to Hematopoietic Growth Factors Guidelines -
March 2020
BCBS Vermont has updated UDENYCA® to be the Preferred Agent with pegfilgrastim-bmez
-
March 2020
Select Health has updated UDENYCA® to be the Preferred Agent with the reference product.
Read More: Select Health has updated UDENYCA® to be the Preferred Agent with Neulasta® -
January 2020
Ventegra has updated UDENYCA® to be the Preferred Pegfilgrastim on their Formulary.
Read More: Ventegra has updated UDENYCA® to be the Preferred Pegfilgrastim on their Formulary -
January 2020
Express Scripts has updated UDENYCA® to be the Preferred Agent with the reference product in the National & Basic Formulary List.
Read More: Express Scripts has updated UDENYCA® to be the Preferred Agent with Neulasta® -
April 2019
UDENYCA® assigned transitional pass-through status April 1, 2019.
Read More: April 2019 Update of the Hospital OPPS -
April 2019
UDENYCA® added to BuyandBill.com.
Read More: Buyandbill.com UDENYCA® -
March 2019
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors Updated to include pegfilgrastim-cbqv*
Read More: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors Updated to include Pegfilgrastim-cbqv
* Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.2.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed July 13, 2020. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Coverage information provided uses data provided by MMIT and is updated periodically. Information provided is not a guarantee of coverage. Please complete a benefit
verification for your patient prior to starting treatment. For assistance please contact Coherus Solutions at 1-844-483-3692 or visit the Coherus Solutions Provider Portal.
Coherus reserves the right to terminate the Coherus Solutions™ program without any notice at any time
Coherus Solutions, UDENYCA Solutions, and LOQTORZI Solutions are trademarks and UDENYCA and LOQTORZI are registered trademarks of Coherus BioSciences, Inc.. All other
trademarks are property of their respective owners. ©2024 Coherus BioSciences, Inc. All rights reserved.US-CMB-0043.3 01/25
Coherus Solutions, UDENYCA Solutions, and LOQTORZI Solutions are trademarks and UDENYCA and LOQTORZI are registered trademarks of Coherus BioSciences, Inc.. All other
trademarks are property of their respective owners. ©2024 Coherus BioSciences, Inc. All rights reserved.US-CMB-0043.3 01/25